8 November 2017 | Geneva −− The World Health Organization (WHO) and the Mundo Sano Foundation are working to make an essential antiparasitic medicine for treatment of Chagas disease widely accessible to children. Treatment with benznidazole in the early stages of infection can cure the Chagas disease, but currently very few people are able to access diagnosis and treatment services.
This investment will help the inventor of the IUB™ intrauterine platform to boost its expansion and increase manufacturing capacity
Chemo Group is already marketing the spherical copper intrauterine device in several European countries
Exeltis US of New Jersey is delighted to announce that they will distribute benznidazole for the treatment of Chagas disease in patients aged 2-12 years old, in the United States following the approval by the FDA on the 29th of August 2017. The approval was secured by the Chemo Research team of the Chemo Group, the parent company of Exeltis Pharmaceuticals, in collaboration with Mundo Sano, DNDi and wide range of skilled and passionate specialists and advisors.
On August 29th, the U.S. Food and Drug Administration (FDA) approved Chemo Research’s New Drug Application (NDA) for benznidazole. This is the first drug ever approved by the FDA to treat Chagas disease.
Exeltis Spain, a company that belongs to the Chemo Group, has acquired Juste's Pharma Unit in an operation that includes the sourcing, research, manufacture (through third parties), promotion and sale of pharmaceutical products for Gynaecology, the Central Nervous System and Primary Care, featuring drugs used to treat insomnia, depression and epilepsy. In the words of Exeltis's General Manager in Spain and Portugal, Alberto Fábregas: “The aim of this operation is to strengthen and increase the company's range of products, and to consolidate Exeltis's presence in the Iberian market, by incorporating the expertise and professionals of Juste's Pharma Unit”.
Exeltis Turkey has received the “Humanity” award in the category of health sector companies for a fourth time. This award is given each year by Kariyer.net, one of the largest employment companies in Turkey, to the companies that respond with the highest speed and efficiency to job applications managed through this portal. The objective of this initiative is to give recognition to the most successful projects carried out in the Human Resources sector.
Exeltis has arrived in Spain with a number of scientific conferences, called Exeltis Days, bringing together over 150 specialists in Gynaecology and Obstetrics on the 3rd and 4th of February in Madrid, in order to report the latest innovations in Europe in various areas of gynaecology. The goal of the company is to accompany women throughout every stage of their lives (from fertility, pregnancy and contraception to the menopause) and, with the advice of specialists, present a comprehensive medical handbook that meets the needs and requirements of patients in terms of reproductive health and associated diseases.
At the end of last year, Exeltis in Spain started a new phase full of enthusiasm and expectation. The new sales force met in Madrid for two weeks to learn and find out all about the Exeltis philosophy and its programme of excellence. Led by its director in Spain, Alberto Fábregas, and accompanied by Leandro Sigman, chairman of Chemo Group and Nick Haggar, CEO of Chemo Group, the forty new delegates of Exeltis prepared to make our brand a benchmark in Women's Health, with innovation as its banner and a clear commitment to serving both professionals and patients. From the outset, Exeltis has had a clear protagonist: science.
Exeltis is continuing its globalisation strategy and has begun operations in the Nordic countries. With its headquarters in Stockholm (Sweden), our new branch is preparing the launch of its first product in the country. Our new affiliate initially will be specialized in Woman Healthcare. Exeltis thus strengthens its position in this area where it’s more and more consolidated.